Addendum
Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24
Report documents
-
Addendum
Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24
Dossier assessment
Indication:
Adult patients with squamous-cell carcinoma of the head and neck with progression during/after platinum-based therapy
Result of dossier assessment:
Conclusion of dossier assessment A17-24 unchanged
Additional information
Federal Joint Committee (G-BA)
2017-11-17 A G-BA decision was published.
Project details
- Project no.
- A17-54
- Commission
- Commission awarded on 09.10.2017 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed